Functional Genomics Market Size, Share and Trends Analysis, By Product and Service (Instruments, Consumables & Reagents, Software & Data Analysis Tools, and Services), By Technology, By Application, By End-Use (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, CRO and CDMO, and Hospitals & Diagnostic Laboratories), and By Region, Forecast 2025-2032

Functional Genomics Market Overview and Key Insights:

The functional genomics market size reached USD 10.55 billion in 2024 and is expected to register a revenue CAGR of 13.6% during the forecast period. Functional genomics is a technique to studying the function of genes and gene products, how they are regulated, and the effects of genome-wide variation on an organism’s biology.

Market Drivers:

Surging demand for precision medicine and targeted therapies is a key driver of revenue growth in the functional genomics market. Advances in sequencing technology have allowed for unprecedented genomic and transcriptome profiling of human cancers. Various models for studying human cancers have been produced and well characterized. Functional genomic screens and pre-clinical drug screening platforms have uncovered genetic dependencies that can be targeted by pharmacological therapy. These genetic dependencies can potentially be utilized as biomarkers to predict treatment outcomes.

The rapid growth of functional genomics over the last two decades has enabled breakthrough findings in cancer research, including acute myeloid leukemia (AML) and breast cancer studies. Novel molecular biology tools, including as short hairpin RNA (shRNA) and CRISPR-Cas9, and breakthroughs in bioinformatics have allowed for wider investigation into the physiopathology of AML, resulting in a cure that is within grasp.

On May 2024, Function Oncology, a company transforming precision medicine’s operating system with CRISPR-powered platform technology, has announced an innovative research and development collaboration with Volastra Therapeutics, a company pioneering novel approaches to cancer treatment by targeting a tumor vulnerability known as chromosomal instability (CIN). The agreement combines Function’s CRISPR-enabled tailored functional genomics technology with Volastra’s CIN expertise to broaden patient selection for Volastra’s KIF18A inhibitors across a wide range of solid tumor indications.

Market Opportunity:

Integration with AI & cloud-based platforms and emerging use in agriculture and environmental research acts as opportunities for functional genomics market. The spread of AI has impacted almost every discipline of research, particularly those dealing with massive data, such as functional genomics. Uncovering the links between variations and diseases, epigenetic alterations and gene expression, binding site placements, and regulatory mechanisms has become increasingly appealing, owing to the development and availability of AI tools. Deep architectures can achieve great levels of abstraction and the ability to hierarchically organize enormous volumes of disparate but highly interrelated data, making it more interpretable.

On April 2025, IRBM, an integrated Contract Research Organization (CRO) that specializes in preclinical drug development, has developed a comprehensive Functional Genomics Platform to help with genetic target selection and validation, as well as the generation of disease-relevant cellular models. The platform combines CRISPR-based techniques, screening capabilities, cell engineering, and advanced molecular and cellular analysis to accelerate target discovery and validation. 

Recent Trends:

Emerging trends include integration of AI and machine learning, emphasis on preventive genomics in healthcare, and advances in multi-omics and single-cell technologies.

Historically, people have been diagnosed with diseases using genomic studies. The use of these tests for preventive wellness has grown in recent years due to a sharp decline in cost and a quick expansion of knowledge. Preventive genetic testing may be used to detect dangers to one’s offspring in addition to one’s own risk of illness. Over half of all people carry a genetic variation that results in one of the approximately 5000 so-called monogenic disorders. In India, for example, 1 in 25 people has beta-thalassemia, a condition that requires frequent blood transfusions throughout life.

While preventive genomic screening cannot eliminate disease risk caused by these complex interactions, it can certainly help identify and manage some key risks in situations where a few genomic variants contribute significantly to the overall risk and where lifestyle or therapeutic interventions can delay disease onset or reduce risk.

Restraints & Challenges:

The primary challenge in functional genomics and systems biology is developing bioinformatics tools to combine and interpret data from numerous ‘omics’ platforms, resulting in a comprehensive understanding of cellular systems and networks. Integrating many relational databases, statistically dissecting them, and presenting the results in a human-readable format is a challenging task.

Developing better screening and selection approaches at the single cell level, as well as using advanced reporter systems, will considerably boost functional genomics and genetics research soon.

Product and Service Segment Insights and Analysis:

Based on the product and service, the functional genomics market is segmented into instruments, consumables & reagents, software & data analysis tools, and services.

Software and data analysis tools segment contributed the highest growth rate during the forecasted period. Gene identification has developed rapidly in response to advances in molecular biology tools and improved availability to genomics and functional genomics information. BLAST is a popular bioinformatics tool that uses the similarity search strategy. PROCRUSTES and GeneWise are two other popular software packages. This software predicts genes using a homologous protein’s global alignment to translate open reading frames (ORFs) in a genomic sequence. Gene prediction or gene identification is critical because it allows scientists to distinguish between coding and non-coding portions of a genome, explain genes in terms of function, perform research on the diagnosis, treatment, and prevention of genetic disorders, and so on.

On February 2025, a collaboration lead by DNAstack has announced the start of the Canadian Platform for AI in Health, a new USD 17.5 million project to improve tools for making AI-powered breakthroughs in genomics and healthcare. This groundbreaking collaboration, which includes Autism Speaks, DNAstack, The Hospital for Sick Children (SickKids), PacBio, and Valence, as well as DIGITAL, builds on long-term and coordinated investments to improve patient outcomes by establishing national and international AI infrastructure for genomics and health.

Technology Segment Insights and Analysis:

Based on the technology, the functional genomics market is segmented into CRISPR/Cas9 Technology, RNA Interference (RNAi), Next-Generation Sequencing (NGS), Microarray Technology, and Polymerase Chain Reaction (PCR).

Next-Generation Sequencing (NGS) segment contributed the largest market share in 2024. The introduction of next-generation sequencing (NGS) has caused a paradigm change in genomics research, providing unequalled capabilities for examining DNA and RNA molecules in a high-throughput and cost-effective manner. NGS enables the rapid sequencing of millions of DNA fragments at once, enabling complete insights into genome structure, genetic variants, gene expression levels, and epigenetic alterations.

This capability has opened new avenues for investigating genetic variation, gene expression, epigenetic changes, and microbial diversity. NGS has proven useful in finding disease-causing mutations, discovering novel therapeutic targets, and providing light on complicated biological phenomena, including tumor heterogeneity and developmental processes.

On February 2025, Roche introduced its patented, revolutionary sequencing by expansion (SBX) technique, ushering in a new age of next-generation sequencing. SBX chemistry, when paired with a unique sensor module, provides ultra-fast, high-throughput sequencing that is both adaptable and scalable for a variety of applications. SBX is a revolutionary sequencing technique that employs a complex biochemical process to encode the sequence of a target nucleic acid molecule (DNA or RNA) into a quantifiable surrogate polymer known as an Xpandomer.

Application Segment Insights and Analysis:

Based on the application, the functional genomics market is segmented into drug discovery & development, clinical diagnostics, agricultural genomics, toxicogenomics, and biomarker discovery & validation.

Drug discovery & development segment contributed the largest market share in 2024. The improved throughput of functional genetic screens in recent years has enabled unbiased, genome-scale screenings to address fundamental biological concerns. This approach began with a focus on gene essentiality, which had obvious implications in oncology, but it has subsequently evolved to include the investigation of increasingly complicated phenotypes. The introduction of CRISPR/Cas9-based tools for high-throughput functional genomic screens revolutionized genetic screening methodologies.

Functional genomics-guided medication discovery has been particularly effective in cancer research. Recently, high throughput investigations and meta-analyses of data from breast cancer samples have found numerous additional targets for which existing medications can be repurposed, considerably speeding up the process of drug discovery.

On April 2025, IRBM, an integrated Contract Research Organization (CRO) that specializes in preclinical drug development, has developed a comprehensive Functional Genomics Platform to help with genetic target selection and validation, as well as the generation of disease-relevant cellular models. The platform combines CRISPR-based techniques, screening capabilities, cell engineering, and advanced molecular and cellular analysis to accelerate target discovery and validation.

Geographical Outlook:

Functional genomics market is strategically segmented by geography to provide a comprehensive understanding of regional market dynamic. Discover demand analysis, emerging trends, and growth opportunities shaping market performance across different region and countries.

North America Functional Genomics Market:

North America is registered to have highest market share in functional genomics market in 2024. This is mainly driven by surging demand for precision medicine and targeted therapies and technological advancements in genomic tools. According to the Center of Disease Control and Prevention (CDC), Sickle cell disease (SCD) affects around 100,000 persons in the United States, with more than 90% being non-Hispanic Black or African American, and the remaining 3%-9% being Hispanic or Latino. The predicted life expectancy of persons with SCD in the United States is more than 20 years lower than the average.

On January 2024, Ultima Genomics, Inc., the company that developed a groundbreaking new ultra-high throughput sequencing architecture, has announced the debut and full commercial availability of the UG 100 at the upcoming Advances in Genome Biology and Technology (AGBT) conference. Ultima’s first commercial product, the UG 100 system, uses a novel sequencing architecture with an open silicon wafer to replace many standard flow cells, enabling the USD 100 genome and beyond. The UG 100 is an ultra-high throughput machine designed specifically for high-volume applications.

Asia Pacific Functional Genomics Market:

Asia Pacific is expected to register the fastest growth rate during the forecasted period, driven by emerging use in agriculture and environmental research. Functional genomics allows agricultural researchers to explore how gene expression and regulation affect complex production traits on a genome-wide scale. There are numerous strategies for applying functional genomic approaches, and new high-throughput technologies are increasing the amount and complexity of data collected from functional genomics investigations.

On November 2024, Inocras Inc. and Summit Pharmaceuticals International Corporation have signed a memorandum of understanding (MOU) to collaboratively investigate the commercialization of whole genome sequencing (WGS) analysis services. This alliance intends to change Japanese healthcare by using genomic data and bioinformatics to better understand and treat cancer and other genetic diseases.  

Europe Functional Genomics Market:

Europe is expected to have considerable market share in 2024, driven by expansion of genomic databases and AI-powered platforms. On August 2024, The Medical Research Council (MRC), in conjunction with the Biotechnology and Biological Sciences Research Council (BBSRC), has committed GBP 28.5 million to launch the Human Functional Genomics Initiative programme.  This program will accelerate research into the molecular underpinnings of health and illness by finding causative variations and modelling their impact in disease-relevant cell types at critical periods of development. It will encourage multidisciplinary teams to innovate and collaborate, as well as speed up the translation of functional genomic research into practical benefits for health and wellbeing.

Competition Analysis:

The functional genomics market is characterized by a fragmented structure, with several players competing across various segments and regions. list of major players included in the functional genomics market report are:

• Illumina, Inc.
• Genomics Ltd
• Enhanc3D Genomics Ltd
• Samplix ApS
• ALS Limited
• Arima Genomics
• MEDiC Life Sciences
• Revvity, Inc.
• Phase Genomics, Inc.
• QIAGEN N.V.
• Hoffmann-La Roche Ltd.
• BD Biosciences
• Thermo Fisher Scientific, Inc.
• Integrated DNA Technologies, Inc.

Strategic Developments in Functional Genomics Market:

• In September 2024, Ginkgo Bioworks, which is developing the premier platform for cell programming and biosecurity, has announced the launch of Ginkgo Datapoints, which will help usher in the next era of biotechnology by making AI model training easier and more efficient. Ginkgo Datapoints specializes in producing huge, high-quality biological datasets in a timely manner and at a competitive price per datapoint through a streamlined agreement structure. Ginkgo Datapoints will introduce numerous data generating solutions this fall, including protein characterisation and functional genomics.
• In May 2024, Xaira Therapeutics, a groundbreaking biotech company, has announced a USD 1 billion funding round led by ARCH Venture Partners and Foresite Capital, with participation from F-Prime, NEA, Sequoia Capital, Lux Capital, Lightspeed Venture Partners, Menlo Ventures, Two Sigma Ventures, the Parker Institute for Cancer Immunotherapy (PICI), Byers Capital, Rsquared, and SV Angel. 
• In November 2023, AstraZeneca has launched a unique collaboration with the Medical Research Council (MRC) and the Milner Therapeutics Institute (MTI) at the University of Cambridge to build a new cutting-edge functional genomics laboratory. The facility will join the UK’s Human Functional Genomics Initiative.

Key Advantages for Stakeholders:

Navistrat Analytics’ industry report provides an in-depth quantitative analysis of various market segments, historical and current trends, market forecasts, and dynamics within the global market. The historical years covered in this report are 2022 to 2023, with 2024 serving as the base year for market size calculations. The forecast period extends from 2025 to 2032.

The report includes an executive summary and a comprehensive overview of market drivers, restraints, opportunities, and challenges (DROC), along with insights into regulatory standards. It features detailed analyses such as PORTER’s Five Forces, SWOT, and PESTLE, as well as assessments of technological trends and the competitive landscape.

PORTER’s Five Forces analysis helps stakeholders evaluate the impact of new entrants, competitive rivalry, supplier power, buyer power, and substitution threats, enabling them to assess the level of competition and the attractiveness of the global market. The competitive landscape provides stakeholders with a clear understanding of the current market positions of key players, offering valuable insights into their competitive environment.

Scope And Key Highlights Of The Functional Genomics Market Report:

The Functional Genomics market report offers a detailed analysis of market size, including historical revenue (in USD Billion) data for 2022-2023 and revenue forecasts for 2025-2032 across the following segments:

• Product and Service Outlook (Revenue, USD Billion; 2022-2032)
  • Instruments
  • Consumables & Reagents
  • Software & Data Analysis Tools
  • Services

• Technology Outlook (Revenue, USD Billion; 2022-2032)
  • CRISPR/Cas9 Technology
  • RNA Interference (RNAi)
  • Next-Generation Sequencing (NGS)
  • Microarray Technology
  • Polymerase Chain Reaction (PCR)

• Application Outlook (Revenue, USD Billion; 2022-2032)
  • Drug Discovery & Development
  • Clinical Diagnostics
  • Agricultural Genomics
  • Toxicogenomics
  • Biomarker Discovery & Validation

• End-Use Outlook (Revenue, USD Billion; 2022-2032)
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • CRO and CDMO
  • Hospitals & Diagnostic Laboratories

• Regional Outlook (Revenue, USD Billion; 2022-2032)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Benelux
    • Nordic Countries
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Oceania
    • ASEAN Countries
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Turkey
    • Rest of MEA

Frequently Asked Questions (FAQ) about the Functional Genomics market report